期刊文献+

抗CD52单克隆抗体外源DNA残留量检测方法的建立及验证 被引量:3

Establishment and validation of a method for determination of residual DNA in anti-CD52 monoclonal antibody
原文传递
导出
摘要 目的建立检测抗CD52单克隆抗体原液中残余DNA的方法,并对该方法进行验证。方法利用CHO Host Cell DNA Extraction&Amplification Kit,采用qPCR法检测抗CD52单克隆抗体中宿主细胞残留DNA含量,并进行方法的专属性、线性、准确度、精密度和耐用性验证。结果该方法可以准确定量检测CHO细胞残留DNA含量。专属性验证试验中对照制剂无特异扩增曲线,而CHO细胞上清有明显的扩增曲线;5次试验中标准曲线相关系数R^2均≥0.98,表明该方法线性良好;准确度验证试验中所有试验的加标回收率均在70%~130%范围内;精密度验证试验中所有试验检测结果的相对标准偏差(RSD)均不大于30%;耐用性验证试验中,Proteinase K不同消化温度下检测结果的CV为0.85%,不同稀释倍数的供试品加标回收率在70%~130%范围内,不同稀释倍数外源DNA检测结果CV为4.71%。结论该方法专属性、准确度、精密度、线性和耐用性均符合要求,可采用该试剂盒qPCR法检测外源DNA残留量。 Objective To establish and validate a method for determination of residual host cell DNA in anti-CD52 monoclonal antibody. Methods The residual exogenous DNA was determined by qPCR using CHO Host Cell DNA Extraction Amplification Kit. The method was verified for specificity, linearity, accuracy, precision and durability.Results The residual DNA of CHO cells was accurately quantified by the developed method. No specific amplification curve was obtained by specificity validation test on control reagent, while obvious amplification curve in that on CHO cell supernatant. All the correlation coefficients(R^2) in five tests were not less than 0. 98, indicating high linearity of the method. All the spiked recovery rates in accuracy validation test were 70% ~ 130%. All the relative standard deviations(RSDs)of results of precision validation test were not more than 30%. However, in durability test, the CV of test results of samples digested with protease K at various temperatures was 0. 85%, while the spike recovery rates of samples at various dilutions were 70% ~ 130%, and the CV of determination results of exogenous DNA at various dilutions was 4. 71%.Conclusion The specificity, accuracy, precision, linearity and durability of the method met the relevant requirements.The method was suitable for determination of residual exogenous DNA of anti-CD52 monoclonal antibody by qPCR.
出处 《中国生物制品学杂志》 CAS CSCD 2017年第12期1305-1310,共6页 Chinese Journal of Biologicals
基金 甘肃省科技重大专项(1502FKDA008)
关键词 CD52 单克隆抗体 CHO细胞 残余DNA 实时定量PCR 方法验证 Monoclonal antibody CHO cells Residual DNA Real-time quantitative PCR Method validation
  • 相关文献

参考文献8

二级参考文献92

  • 1饶春明,赵阳,李永红,王军志.应用荧光法测定重组细胞因子中残余DNA含量[J].药物分析杂志,2005,25(12):1417-1419. 被引量:22
  • 2史艳秋,陈畅,顾黎,邹思湘,宋静,王鹏.重组人β干扰素在DHFR^--CHO细胞中的高效表达[J].中国生化药物杂志,2006,27(3):129-133. 被引量:7
  • 3李亮助,刘勇,王贻杰,程海,孙茂盛,邵一鸣.Real-time PCR检测核酸疫苗中宿主基因组残留DNA[J].中国生物制品学杂志,2007,20(6):439-441. 被引量:8
  • 4EU. Position statement on the use of tumorigenic cells of human origin for the production of biological and bioteehnological medicinal products. The European Agency for the Evaluation of Medieinal Products : Evaluation of medicinal products for human use. CPMP/BWP/1143/ 00 2001.
  • 5FDA. Points to consider in the manufacture and testing of monoclonal antibody products for human use. US Department of Health and Human Services,Food and Drug Administration, Center for Biologics Evaluation and Research 1997.
  • 6WANG Jun-zhi(王军志).Research & Development and Quality Control of Biotechnical Drugs(2nd Ed)(生物技术药物研究开发和质量控制)(第二版).Beijing(北京):Science Press(科学出版社),2007.98.
  • 7Singer VL, Jones LJ, Yue ST, et al. Characterization of PicoGreen reagent and development of a fluorescence - based solution assay for double - stranded DNA quantitation. Anal Biochem, 1997,249 ( 2 ) : 228.
  • 8苗玉发,王欣,沈连忠,李波.治疗性HIV腺病毒载体疫苗的生物分布[J].毒理学杂志,2007,21(4):313-314. 被引量:3
  • 9Yang H, Zhang L, Galinski M. A probabilistic model for risk assessment of residual host cell DNA in biological products [Jl. Vaccine, 2010,28 (19) :3308-3311.
  • 10Sheng-Fowler L, Lewis AMJr, Peden K. Issues associated with residual cell-substrate DNA in viral vaccines [J]. Biologicals, 2009, 37 (3): 190-195.

共引文献73

同被引文献30

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部